Motivated by the improved therapeutic properties of intravenously or intratumorally administered immunotherapy agents when fused to the CBD derived from the A3 domain of von Willebrand factor (CBD) (22), which leads to active retention in the exposed tumor stroma, we fused the CBD to the C terminus (IL-7–CBD), N terminus (CBD–IL-7), or C and N termini (CBD–IL-7–CBD) of murine IL-7 and chose to proceed with IL-7–CBD, which had a higher yield (5.8 mg/liter) than other candidates (CBD–IL-7, 4.8 mg/liter; and CBD–IL-7–CBD, 3 mg/liter) (Fig. 1A and fig. This evidence concerns the gene VWF and neoplasm.